. Patients with non-steroid ventricular leads had signifi cantly higher threshold compared to steroid leads at 1, 3, 6-month (6-month 1.0 ± 0.3 vs. 0.6 ± 0.2 V at 0.4 ms, p < 0.001 (Cardiol J 2013; 20, 4: 431-438) 
Introduction
Rising pacing threshold after implantation is a well-known phenomenon in endocardial pacing, caused by formation of a fi brotic capsule at the lead-tissue interface due to infl ammatory reactions [1] . Use of anti-inflammatory drugs like dexamethasone has been established for many years to suppress acute and chronic cellular infl ammation and release of infl ammatory mediators, resulting in lower pacing threshold and pacing energy [1, 2] .
With the development of pacemaker (PM) therapy, rate responsive sensors and enhanced diagnostic features necessitated the improvement of lead technology to reduce current drain and extend PM longevity [3] . Small surface, high-impedance pacing leads were able to decrease current drain, however the smaller surface area was initially associated with worse sensing capabilities and higher pacing threshold. Several studies have proven the benefi cial short and long-term effects of steroid pacing leads [4] [5] [6] [7] , however, no study has been conducted yet to directly compare small surface endocardial pacing leads with or without steroid-eluting collar with other with identical shape and structure.
Home Monitoring ® is an established remote monitoring system providing remote patient follow-up and monitoring while using automatic wireless communication and home transmitters. It is a reliable method to effectively reduce hospital visits [8, 9] , hospital visit related costs and improve patient safety [10, 11] . The use of remote monitoring system has not yet been established to follow-up acute and chronic lead performance in PM patients with steroid or non steroid-eluting leads.
This randomized, multicenter clinical study was designed to compare small porous surface atrial and ventricular pacing leads with same shape and structure, with 0.27 mg of dexamethasone acetate (DXA) collar or with no steroid-eluting surface.
Methods

Patient population
Patients included in the analysis were consecutively selected from 3 investigational international centers (2 centers in Germany, 1 center in Hungary) based on pre-specifi ed inclusion and exclusion criteria. Inclusion criteria included patients with standard PM indication referred to the hospital if they were geographically stable and available for follow-up visits at the center. Patients were excluded if they had life expectancy of less than 6 months, planned cardiac surgery in the next 6 months, enrolled in another cardiac clinical investigation or had other medical devices that may have had an interaction with the implanted PM. The clinical investigation was conducted according to the ethical principles of the Declaration of Helsinki (2008) 
Investigational leads
The SIELLO T/JT leads are a family of 5.9 F, steroid-eluting, transvenous, endocardial bipolar passive-fi xation leads. The SIELLO T is a straight lead, while the SIELLO JT carries a J-shaped distal end. The SIELLO T lead is available in 53 cm and 60 cm length, while the SIELLO JT lead varies in lengths of 45 cm and 53 cm. The leads have an isodiametric structure and silicone insulation. The inner and outer conductors consist of quadruple wire coils. They are covered by polyurethane overlay for better gliding. The SIELLO T/JT leads have an IS-1 connector and a 12 mm pole distance. The SIELLO T/JT electrode tip has a fractal iridium coating and an active surface area of 2.1 mm The BPPU T/JT leads are completely identical in shape and structure to the SIELLO T/JT leads but not featuring steroid eluting collar. Instead of the steroid eluting collar, there is a pure silicone dummy collar mounted with the same dimensions as the steroid eluting collar of the SIELLO T/JT leads.
Randomization procedure
Patients were randomized in a 1:1 fashion to receive either steroid-eluting SIELLO T/JT investigational lead or non-steroid BPPU T/JT investigational lead with the same shape and structure.
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Device and lead implantation procedure
All patients had undergone conventional transvenous PM implantation based on current standards. Commercially available single and dual chamber PM devices (Biotronik) were used in the study with remote monitoring capabilities available. Lead and device testing during the implantation procedure was performed based on accepted standards. No additional test was required by the study protocol.
Device programming
Devices were programmed to AAI(R), VVI(R) or DDD(R) mode depending on the leads and PM implanted. Devices with Home Monitoring ® available were recommended to program it ON, unless not eligible for the patient.
Patient follow-up, device interrogation
Patients had an ambulatory follow-up within 1-week after device implantation (pre-discharge testing) and 1, 3, 6-month thereafter until the end of the trial or in case of an adverse event. The mean follow-up time of the study was 6 months. Home Monitoring ® data were received and evaluated in patients with remote monitoring on a daily basis. Interrogation data at regular follow-up procedures and at any device-related adverse events were sent to the interrogation core laboratory in Berlin, Germany for further evaluation.
Defi nitions and study endpoints
The primary end point of the study was the effi cacy assessment of SIELLO T/JT leads supported by the collection of measured data (sensing, pacing impedance, and pacing threshold) during the implantation and follow-up procedures with special focus on the atrial and ventricular threshold evaluated at 0.4 ms impulse width and compared to the non-steroid BPPU T/JT leads. The secondary endpoint was lead safety data on adverse events collected during the entire study duration.
Statistical analysis
Continuous variables are expressed as mean ± standard deviation. Categorical data are summarized as frequencies and percentages. The randomization process was carried out using PROC PLAN in SAS with a block length of 6. The lead evaluation data were compared between patient groups of steroid-eluting and non steroid-eluting pacing leads, T-test for independent samples or Mann-Whitney-U test was used, as appropriate. All tests were 2-sided and a p-value of < 0.05 was considered statistically signifi cant.
Results
Steroid or non-steroid eluting leads were implanted in 88 patients (35 female) with the mean age of 72.9 ± 10.1 years in the steroid-eluting lead group (42 patients) and 73.4 ± 9.1 years in the non steroid-eluting lead group (46 patients).
Clinical characteristics
Patients with implanted non-steroid lead had trend towards more frequent valvular disease (30.4% vs. 16.7%, p = 0.130) and cardiomyopathy (17.4% vs. 7.4%, p = 0.147). Incidence of hypertension, diabetes mellitus and renal insuffi ciency and drug treatment was similar in both groups (data not shown).
Indication of permanent PM therapy is summarized in Table 1 . Twenty (47.6%) patients with steroid-eluting leads and 16 (34.8%) patients with Lead and device implantation procedure Implantation of right atrial leads was primarily performed via left cephalic access (60.9%), less often via the subclavian vein (39.1%). Ventricular leads were implanted via the left or right cephalic vein (57.8%), less often via the left or right subclavian vein (42.2%).
The distribution of implanted leads per patient and implanted PM models are summarized in Table 2 . Non-steroid BPPU JT atrial lead and BPPU T ventricular leads were implanted in 30.7% of the patients, while steroid-eluting SIELLO JT atrial lead and SIELLO T ventricular lead were present in 27.3% of the patients. Single-chamber devices and ventricular lead only with steroid-eluting tip were implanted in 3.4% of the patients, in 5.7% with no steroid tip. Both study and non-study leads were implanted in 15.9% and 17.0% of the total patient population, respectively.
The ventricular lead position was apical in 45.2% of steroid eluting leads and 43.5% of non--steroid leads, while septal in 54.8% of steroid--eluting leads and 56.5% of non-steroid leads. The atrial lead was implanted at the right atrial appendage in all patients.
Lead implantation procedure as assessed by the implanting physician was very easy or easy in all atrial leads (100%), while declared to be the same in 96.5% of ventricular leads. Moderately diffi cult or diffi cult implantation of the ventricular leads of either type was reported in 3.5% of the total patient population.
The total fl uoroscopy time was 2.8 ± 2.7 min (median: 1. 
Evaluation of lead integrity and lead parameters, device longevity
Atrial lead integrity parameters and sensing function evaluated at implantation, pre-discharge follow-up and at 1, 3, 6 months follow-up procedures were within normal limits in steroid and non-steroid eluting atrial leads. There was a signifi cant difference found steroid-eluting and non steroid-eluting atrial leads in the pacing impedance at 1-month follow-up (1-month 774 ± 91 vs. 700 ± ± 111 Ohm, p = 0.012).
The atrial threshold was signifi cantly higher in non-steroid leads as compared to steroid-eluting leads at 1-week and at 1, 3 and 6 month follow-up with a peak at 1-month (1-month 1.4 ± 0.6 vs. 0.7 ± 0.3 V at 0.4 ms, p < 0.001) ( Table 3 ). The mean value of atrial threshold in non-steroid leads was increasing until the 3-month follow-up, and slightly decreasing until the 6-month follow-up, then remained stable (Fig. 1) .
Ventricular steroid-eluting leads had stable and similar sensing and lead impedance as compared to non-steroid leads at implantation and during follow-up. The ventricular pacing impedance was slightly higher in steroid-eluting leads at pre--discharge follow-up as compared to non-steroid--eluting ventricular leads (911 ± 138 vs. 840 ± ± 128 Ohm, p = 0.015). Patients with non-steroid ventricular leads had signifi cantly higher threshold compared to steroid-eluting leads at 1, 3, 6-month follow-up visits with clear early separation at 1 month, remaining stable at the 6-month follow--up (6-month 1.0 ± 0.3 vs. 0.6 ± 0.2 V at 0.4 ms, p < 0.001) ( Table 3) . 
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Home Monitoring ® data of steroid-eluting and non-steroid ventricular lead performance were available in 51 (58%) patients implanted with ventricular steroid or non-steroid leads. Figure 1 shows ventricular threshold data at on-site follow-up visits, as well as weekly Home Monitoring ® data. We found excellent correlation between on-site follow--up visit assessments and Home Monitoring ® data Table 3 . Atrial and ventricular pacing threshold of SIELLO JT and BPPU JT leads. We also calculated the device longevity for the steroid vs. non-steroid-eluting ventricular leads, using the standard programming of VVI 60 bpm, 100% pacing, and a stimulation pulse width of 0.4 ms. Patients implanted with a steroid-eluting lead had 2 ± 5 months additional device longevity, depending on the type of the implanted PM.
Adverse events
A total of 45 adverse events (0.51 events/ /patient) have been reported during the duration of the study. All adverse events are sorted by underlying cause and severity, as adverse event (AE) or serious adverse event (SAE) in Table 4 . Two-thirds of AE's was classified as SAE. Seven AE's were reported as cases of atrial fibrillation. One AE was reported with symptoms of chronotropic incompetence, device reprogramming eliminated the symptoms. A total of 10 lead related adverse device effects occurred, 5 of them were resolved by PM reprogramming. Four SIELLO T/JT lead and 1 BPPU T/JT lead required lead reposition procedure during the study, all of the lead dislodgements occurred in the early postoperative period (BPPU T non-steroid lead 1 day after implantation, SIELLO T/JT steroid leads 0-2 days after implantation). During the follow-up 3 patients died, without any relation to the investigational study leads (1 of sepsis, 1 of multiple organ failure and 1 of sudden cardiac death).
Discussion
To our knowledge, this is the fi rst randomized multicenter study directly comparing steroid--eluting and non-steroid eluting small surface atrial and ventricular lead performance. Our study demonstrated that atrial and ventricular small surface pacing leads with steroid collar had signifi cantly lower pacing threshold compared to non-steroid leads. Both leads were safe and effi cient as additionally confi rmed by Home Monitoring ® . Previous studies have shown that standard steroid-eluting pacing leads either with dexamethasone acetate or phosphate compound effi ciently reduce the pacing threshold rise after implantation caused by infl ammatory reactions at the tissue--lead interface [1, 7, 12] . This effect was stable and maintained during 5-or 10-year follow-up [13, 14] . Similarly benefi cial effects of steroid-eluting coating were observed in active fixation atrial pacing leads [15] .
Small surface, higher impedance pacing leads were able to reduce battery current drain, however the small surface area was associated with worse sensing capabilities and higher pacing threshold [16, 17] . Therefore, there is a rationale to use steroid eluting surface in small surface pacing leads.
The main fi nding of the current study was that patients with non steroid-eluting atrial leads had signifi cantly higher threshold compared to steroid--eluting leads at 1-week and 1, 3 and 6-month follow-up. Consistent with these fi ndings, patients with non-steroid ventricular leads showed signifi cantly higher thresholds compared to steroid--eluting pacing leads at 1, 3, 6-month follow-up. Previous clinical studies showed similar results when comparing steroid-eluting conventional surface electrodes with non-steroid-eluting leads [18] or when comparing high-impedance steroid eluting leads with conventional surface steroid--eluting leads [5] .
Additional strength of this trial is that remote Home Monitoring ® system was proven to be efficient, following changes in ventricular threshold 
